Learn how to find the current needed to deflect a compass needle in this step-by-step physics tutorial! Explore the principles of magnetic fields, current-carrying wires, and the interaction with a ...

Whether you have privacy concerns or you just want to freely tinker, these are our favorite alternatives to stock Android.

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Compass’ private exclusive listings feature may have started a tech race nationally, but it joined several similar models already existing in Texas.

That didn’t take long. Moderna said this morning that the FDA will now review its experimental mRNA flu vaccine, reversing its decision denying a review because of a dispute over the vaccine’s ...

Investing.com - Canaccord Genuity raised its price target on Compass Therapeutics (NASDAQ:CMPX) to $13.00 from $10.00 on Wednesday, while maintaining a Buy rating on the stock. The new target ...

GroupM launched a tool in beta on Monday designed to help marketers determine the potential ethical risks associated with a data-driven campaign from a consumer perspective. Launched in partnership ...

Compass Group PLC CPG shares slid 1.18% to £21.72 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.17% to 10,171.76.

Shares of Compass Group PLC CPG shed 1.93% to £21.81 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.58% to 10,207.80.

Shares of at least four other developers were up by mid-single digits to low-double digits at certain points on Tuesday.

By Sahil Pandey and Christy Santhosh Feb 17 (Reuters) - Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the drug developer's ...